NRAS Q61R

Reports 3 in KLA · GLA · CCLA

Bars show the reported allele-fraction range on a 0 to 50 percent axis.

Position in NRAS 2 catalogued variants in this gene

Same region Q61K

Pathway and targeted therapy

Variant in the RAS-MAPK pathway. Repurposed drugs already used in the clinic for this pathway: trametinib and other MEK inhibitors.

Open and recent trials (3 in vascular / lymphatic anomalies for trametinib)

• 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs ACTIVE NOT RECRUITING NCT07549646 · PHASE2 · WHO ICTRP
• Trametinib Treatment for Complicated Vascular Anomalies ACTIVE NOT RECRUITING NCT07072403 · PHASE1, PHASE2 · WHO ICTRP
• A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies NOT YET RECRUITING NCT07767877 · WHO ICTRP

Primary sources 5

1. Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.

   Brown G, McNab S, Keogh S, Massie J, Eastaugh L, Pathmanathan L, Bertinetti M, Sullivan M, Orme L, Cloney T, Brown NJ, Tan TY, Quin R, Pertile M, Moon A, Bekhit E, Penington T. · Case Rep Pediatr · 2026
2. NRAS mutation in a central conducting lymphatic anomaly and PPFIBP1::ROS1 fusion in a Gorham-stout disease patient.

   Yang G, Ren H, Wang J, Chen W, Li X, Chen S, Chen H, Zhao L, Fan W, Xiao S. · Hum Mol Genet · 2026
3. Genomic profiling informs diagnoses and treatment in vascular anomalies.

   Li D, Sheppard SE, March ME, Battig MR, Surrey LF, Srinivasan AS, Matsuoka LS, Tian L, Wang F, Seiler C, Dayneka J, Borst AJ, Matos MC, Paulissen SM, Krishnamurthy G, Nriagu B, Sikder T, Casey M, Williams L, Rangu S, O'Connor N, Thomas A, Pinto E, Hou C, Nguyen K, Pellegrino da Silva R, Chehimi SN, Kao C, Biroc L, Britt AD, Queenan M, Reid JR, Napoli JA, Low DM, Vatsky S, Treat J, Smith CL, Cahill AM, Snyder KM, Adams DM, Dori Y, Hakonarson H. · Nat Med · 2023
4. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.

   Barclay SF, Inman KW, Luks VL, McIntyre JB, Al-Ibraheemi A, Church AJ, Perez-Atayde AR, Mangray S, Jeng M, Kreimer SR, Walker L, Fishman SJ, Alomari AI, Chaudry G, Trenor Iii CC, Adams D, Kozakewich HPW, Kurek KC. · Genet Med · 2019
5. Somatic NRAS mutation in patient with generalized lymphatic anomaly.

   Manevitz-Mendelson E, Leichner GS, Barel O, Davidi-Avrahami I, Ziv-Strasser L, Eyal E, Pessach I, Rimon U, Barzilai A, Hirshberg A, Chechekes K, Amariglio N, Rechavi G, Yaniv K, Greenberger S. · Angiogenesis · 2018

Mentioned in 1,690 publications indexed by Europe PMC.